Oberlander Tim F, Warburton William, Misri Shaila, Aghajanian Jaafar, Hertzman Clyde
Early Human Experience Unit, Centre for Community Child Health Research, Vancouver, BC, Canada.
Br J Psychiatry. 2008 May;192(5):338-43. doi: 10.1192/bjp.bp.107.037101.
Late-gestational serotonin reuptake inhibitor (SRI) exposure has been linked to adverse neonatal outcomes; however, the impact of timing and duration of exposure is unknown.
To determine whether late-gestational exposure to an SRI is associated with increased risk of adverse neonatal outcome relative to early exposure.
Population-based maternal and neonatal health records were linked to prenatal maternal prescription records for an SRI medication (n=3500).
After controlling for maternal illness and duration of exposure, using propensity score matching, neonatal outcomes did not differ between late and early exposure (P>0.05). After controlling for maternal illness, longer prenatal exposure increased the risks of lower birth weight, respiratory distress and reduced gestational age (P<0.05).
Using population health data, length of gestational SRI exposure, rather than timing, increased the risk for neonatal respiratory distress, lower birth weight and reduced gestational age, even when controlling for maternal illness and medication dose. These findings highlight the importance of distinguishing the specific impact of medication exposure from exposure to maternal illness itself.
妊娠晚期血清素再摄取抑制剂(SRI)暴露与不良新生儿结局有关;然而,暴露的时间和持续时间的影响尚不清楚。
确定相对于早期暴露,妊娠晚期暴露于SRI是否会增加不良新生儿结局的风险。
基于人群的孕产妇和新生儿健康记录与SRI药物的产前孕产妇处方记录相关联(n = 3500)。
在控制了孕产妇疾病和暴露持续时间后,使用倾向评分匹配,晚期和早期暴露之间的新生儿结局没有差异(P>0.05)。在控制了孕产妇疾病后,更长的产前暴露增加了低出生体重、呼吸窘迫和孕周缩短的风险(P<0.05)。
使用人群健康数据,即使在控制了孕产妇疾病和药物剂量后,妊娠期间SRI暴露的时长而非时间增加了新生儿呼吸窘迫、低出生体重和孕周缩短的风险。这些发现凸显了区分药物暴露与孕产妇疾病本身的特定影响的重要性。